Latest Anthrax Stories
ANNAPOLIS, Md., Nov. 20, 2014 /PRNewswire/ -- PharmAthene, Inc.
PINE BROOK, N.J., Sept. 22, 2014 /PRNewswire/ -- Elusys Therapeutics, Inc.
PRINCETON, N.J., Sept. 19, 2014 /PRNewswire/ -- Soligenix, Inc.
ANNAPOLIS, Md., Sept. 10, 2014 /PRNewswire/ -- PharmAthene, Inc.
ANNAPOLIS, Md., Sept. 9, 2014 /PRNewswire/ -- PharmAthene, Inc.
PRINCETON, N.J., Aug. 11, 2014 /PRNewswire/ -- Soligenix, Inc.
Awarded $2.1 million in additional funding PRINCETON, N.J., Aug. 1, 2014 /PRNewswire/ -- Soligenix, Inc.
Antibiotic resistance could bring about the “next pandemic,” turning run-of-the-mill disease-causing bacteria into nearly untreatable illnesses, the US Centers for Disease Control and Prevention (CDC) warned on Tuesday.
Milestone Achieved under $9.4 Million NIAID Cooperative Grant PRINCETON, N.J., July 9, 2014 /PRNewswire/ -- Soligenix, Inc.
New York personal injury lawyer David Perecman of The Perecman Firm weighs in on the anthrax scare at the U.S.
Bacillus anthracis is a Gram-positive spore-forming, rod-shaped bacterium, with a width of 1-1.2Âµm and a length of 3-5Âµm. It can grow in aerobic or anaerobic conditions. It is the only known bacterium to synthesize a protein capsule and the only pathogenic bacterium to carry its own adenylyl cyclase virulence factor. They form oval spores located centrally in a non-swollen sporangium. These spores are highly resilient and can survive extreme temperatures, low-nutrient environments, and...
- An armed gangster.